Suppr超能文献

一例对选择性褪黑素MT1/MT2受体激动剂雷美替胺有反应的丛集性头痛

A Cluster Headache Responsive to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.

作者信息

Imai Noboru

机构信息

Department of Neurology, Japanese Red Cross Shizuoka Hospital, Japan.

出版信息

Intern Med. 2016;55(17):2483-5. doi: 10.2169/internalmedicine.55.6621. Epub 2016 Sep 1.

Abstract

Patients with cluster headaches occasionally fail to respond to conventional preventive treatments. We herein report a case of a patient with a cluster headache in which the symptoms were refractory to conventional preventive treatments except for high-dose glucocorticoids. The headache attacks occurred daily while sleeping, thus the patient suffered from insomnia. Ramelteon, a selective melatonin receptor agonist and a member of a new class of insomnia therapies, completely suppressed the attacks during sleep and provided rapid relief from insomnia. This is the first English case report to describe the efficacy of ramelteon as a preventive treatment for cluster headaches.

摘要

丛集性头痛患者偶尔对传统预防性治疗无反应。我们在此报告一例丛集性头痛患者,其症状除高剂量糖皮质激素外对传统预防性治疗无效。头痛发作每天在睡眠时出现,因此患者患有失眠症。雷美替胺是一种选择性褪黑素受体激动剂,属于新型失眠治疗药物,它完全抑制了睡眠期间的发作,并迅速缓解了失眠症状。这是第一份描述雷美替胺作为丛集性头痛预防性治疗药物疗效的英文病例报告。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验